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AbstrACt
Objective Neisseria meningitidis carriage prevalence 
has known variation across the lifespan, but it is unclear 
whether carriage varies among meningococcal capsular 
groups. Therefore, we aimed to characterise group-specific 
meningococcal carriage by age group and world region 
from 2007 to 2016.
Design Systematic review and meta-analysis.
Data sources MEDLINE, Embase, Global Health 
Database, WHO Global Health Library, Web of Science, 
Current Contents Connects, China National Knowledge 
Infrastructure and Wanfang were systematically searched. 
Database searches were conducted through July 2018 and 
Google Scholar forward searches of included studies were 
conducted through August 2018. References of included 
studies and relevant conference abstracts were also 
searched to identify additional articles for inclusion.
Eligibility criteria Studies were eligible for inclusion if 
they reported capsular group-specific meningococcal 
carriage in a healthy population of a specified age group 
and geographical region. For this review, only studies 
conducted between 2007 and 2016 were included.
Data extraction and synthesis Data were independently 
extracted by two authors into Microsoft Access. Studies 
were assessed for risk of bias using the Joanna Briggs 
Institute Critical Appraisal Checklist for Studies Reporting 
Prevalence Data. Studies eligible for inclusion in 
quantitative analyses by pre-specified age groups were 
pooled using random effects meta-analyses. Results are 
reported by capsular group, age group and WHO region. 
Where meta-analyses were not appropriate, study results 
were discussed narratively.
results 7511 articles were identified and 65 were eligible 
for inclusion. Adolescents and young adults were the 
focus of many studies (n=24), especially in the Americas 
and Europe. Studies from China and Africa, typically, 
included data from a wider age range. The overall carriage 
prevalence varied markedly by age group and region. 
Based on the available data, 21 studies were included in 
meta-analyses reporting serogroup carriage for: all ages 
in Africa, 18–24-year olds in the Americas, and 11–17 
and 18–24-year olds in Europe. Capsular groups W, X, Y 
and ‘other’ (non-ABCWXY, including non-groupable) were 
the most prevalent in Africa, and 5–17-year olds had 
higher carriage prevalence than other age groups. ‘Other’ 
serogroups (11.5%, 95% CI 1.6% to 16.1%) were the most 
common among 18–24-year olds from the Americas. In 
Europe, 18–24-year old were carriers more frequently than 
11–17-year olds, and groups B (5.0%, 95% CI 3.0% to 
7.5%), Y (3.9%, 95% CI 1.3% to 7.8%) and ‘other’ (6.4%, 
95% CI 3.1% to 10.8%) were the most commonly carried 
in the older age group.
Conclusions Of the age groups included in the analysis, 
carriage patterns by age were similar across capsular 
groups within a region but differed between regions. Data 
gaps remain for age- and capsular group-specific carriage 
in many regions, especially in the Eastern Mediterranean 
and South-East Asia. As such, clear and robust conclusions 
about the variation of capsular group-specific carriage by 
age group and WHO region were unable to be determined.
PrOsPErO registration number CRD42017074671.
bACkgrOunD
Invasive meningococcal disease (IMD) is a 
severe bacterial infection caused by Neisseria 
meningitidis. IMD most commonly presents 
as meningitis and septicemia, and despite 
advances in medical care, continues to have a 
case fatality rate of approximately 10%–15% 
and debilitating sequelae in 10%–15% of 
survivors.1 2 The incidence of IMD varies glob-
ally, with the highest burden in the African 
meningitis belt and in young children and 
adolescents.3 Historically, pharyngeal carriage 
of the bacterium was estimated to occur in 
approximately 10% of the general population 
at any one point in time, with most people 
becoming carriers at multiple points in their 
strengths and limitations of this study
 ► This is the first review investigating serogroup-spe-
cific meningococcal carriage by age group.
 ► A comprehensive literature review was performed 
with additional granular data requested from au-
thors for meta-analyses.
 ► Meta-analyses were conducted for all ages in 
Africa, 18–24-year olds in the Americas and 11–17-
year olds and 18–24-year-old in Europe.
 ► Other regions and age groups were synthesised nar-
ratively due to differences in reported age groups or 
paucity of data.
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lifetime.4 Recent studies estimate that carriage prevalence 
peaks during late adolescence in Europe and early adoles-
cence in Africa.5 6 As such, persons in these age groups 
are likely to be important transmitters of the disease in 
these regions.
There are 12 capsular groups of N. meningitidis, six of 
which cause the majority of disease globally—A, B, C, W, 
X and Y. Currently, vaccines are available targeting five of 
the 12 serogroups: polysaccharide and conjugate vaccines 
for serogroups A, C, W and Y, and broad protection 
recombinant protein-based vaccines targeting serogroup 
B.7 Since IMD is primarily transmitted through carriage, 
to inform appropriate vaccine policies, it is important 
to understand the serogroups being carried and if these 
serogroups differ by age group. Conjugate vaccines 
can effectively induce indirect herd immunity through 
clearing carriage, at least for serogroup C, as seen in the 
United Kingdom post-MenC vaccine introduction.7 8
Although reviews and analyses have been conducted 
to determine the overall carriage prevalence by age, 
no review has attempted to quantify serogroup-specific 
carriage in different age groups.5 6 Understanding the 
age group with the highest level of carriage, and which 
serogroups they carry, is important to better understand 
disease transmission and determine optimal target ages 
for vaccination.7 9 As countries introduce vaccination poli-
cies targeting age groups with high overall carriage levels, 
it is important to understand if other age groups could 
have a low overall carriage prevalence yet be important 
carriers of certain capsular groups, and, thus, disease 
transmitters and source of potential outbreaks. There-
fore, we aimed to analyse carriage studies conducted in 
persons of defined ages from 2007 to 2016 in order to 
elucidate any differences in the carriage of meningo-
coccal serogroups by age group.
MEthODs
search strategy and data sources
We conducted a systematic review of the literature to iden-
tify meningococcal carriage studies in specific age groups 
conducted between 1st January 2007 and 31st December 
2016 (PROSPERO number CRD42017074671). Two 
authors (MP and HS) searched six databases (MEDLINE, 
Embase, Global Health Database, WHO Global Health 
Library, Web of Science and Current Contents Connects). 
Additionally, a native speaker (YL) searched two Chinese 
literature databases (China National Knowledge Infra-
structure and Wanfang). Search terms were developed for 
MEDLINE (online supplementary table 1) and adapted 
for the remaining databases. Google Scholar forward cita-
tions, relevant conference abstract lists, and references of 
identified studies and reviews were also searched. Data-
base searches were last conducted in July 2018 and Google 
Scholar searches in August 2018. We did not exclude any 
article based on language, and Google Translate was used 
to assist with screening. If questions remained, we sought 
translation assistance.
Inclusion and exclusion criteria
Studies were considered for inclusion if they reported 
capsular group-specific pharyngeal carriage in a healthy 
population of a defined age group, provided clear 
geographical location of participants and were reason-
ably representative of the general population. If the 
age of participants was not reported but referred to as a 
generic age group (eg, adolescents, university students, 
elementary students, etc), the exact ages were requested 
from the authors.
Studies were ineligible for inclusion if they only 
provided disease data or were carriage studies among 
cases or close-contacts of cases. Studies that had unclear 
reporting of serogroups or participants sampled, unclear 
geographical location or year, only tested for one sero-
group or serogrouped/reported <75% of positive 
carriage specimens were also excluded. Studies reporting 
secondary data, case studies, commentaries or reviews 
were also ineligible for inclusion.
Data collection and management
Two authors (MP and HS) independently screened the 
titles and abstracts of all studies and the relevant full-text 
articles. Studies selected for inclusion were independently 
extracted into Microsoft Access by two authors (MP and 
YL) using a piloted extraction template. One author 
screened and extracted the Chinese articles (YL) with 
input from another (MP). Any disagreement in eligibility 
or extractions was discussed and a consensus reached 
before proceeding.
Quality assessment
The included studies were assessed for quality using a 
modified Joanna Briggs Institute Checklist for Prevalence 
Studies and given a low, medium, or high risk-of-bias 
score.10 Factors assessed included the sampling frame-
work and recruitment methods, calculation of adequate 
sample size, and detailed description of study method-
ologies and population. Since no methodological ‘gold 
standard’ exists, the validity of the methodologies used 
was not assessed.
Data analysis
In order to have standardised age groups for meta-anal-
yses, we requested detailed data from the authors of 
eligible studies. The age groups were pre-specified based 
on life stage as follows (in years): 0–4, 5–10, 11–17, 
18–25, 26–29, 30–49, 50–64 and ≥65. Serogroup-spe-
cific meta-analyses for serogroups A, B, C, W, X, Y and 
‘other’ (non-ABCWXY, including non-groupable) were 
conducted stratified by age group and WHO region 
if data from at least three studies were available for all 
serogroups in a given age group and WHO region. We 
conducted all analyses in StataIC 13 (64-bit) using the 
metaprop command and reported the results using a 
random-effects model with the Freeman-Tukey transfor-
mation and exact binomial CIs (StataCorp, 2013)11 Since 
sample sizes for multiple covariates were expected to be 
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small and there were insufficient studies, meta-regression 
was not considered feasible. Heterogeneity was measured 
using I2 values, and classified as low (I2<50%), moder-
ately high (50%≤I2<75%) or high (I2≥75%).
Multi-site studies performed at the same time point 
were combined so that each data point represented one 
country and one time point. Only baseline data were 
included from longitudinal cohort studies or repeat 
cross-sectional studies with a nested cohort. Studies 
with a swabbed sample size <10 in a particular age 
group were not included in the analyses (n=2) due to 
the use of the Freeman-Tukey transformation and its 
degradation with extremely sparse data.11 If a study 
included multiple methodology comparisons (eg, naso-
pharyngeal vs oropharyngeal swab, slide agglutination 
vs PCR), the results from one method were included in 
the review. The results from the methodology compar-
ison studies and the notation of which methodology was 
included in the review are detailed in online supple-
mentary table 2.
Patient involvement




Sixty-five studies reporting serogroup-specific carriage 
among a defined age group met our inclusion criteria 
(figure 1). Forty-three were one-time cross-sectional 
studies, 12 were repeat cross-sectional studies, five were 
repeat cross-sectional studies with a nested cohort (either 
intentional or unintentional), four were cohort studies 
and one was a randomised controlled trial. Almost half of 
the studies were from China, and the rest were from Amer-
icas or Europe. However, studies with the largest sample 
sizes were from the African region with an average of 3282 
participants sampled per country per year. Study popula-
tions varied in their coverage of MenB, MenA, MenACWY 
and MenC vaccinations (online supplementary table 3).
Swabbing and laboratory methods varied between 
studies. Fifty-five studies reported swabbing the ‘posterior 
pharynx’, ‘oropharynx’ or ‘pharynx,’ while nine swabbed 
the ‘nasopharynx’ and one swabbed both the sites in 
order to compare the methodology. To characterise the 
capsular group, 20 studies used agglutination methods 
alone, 34 used genetic methods (eg, PCR, whole genome 
sequencing) alone or to supplement agglutination and 
11 did not report the method used.
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart of included studies.
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Thirteen studies reported the results of multiple meth-
odologies for detecting the meningococcus or grouping 
the carriage samples (online supplementary table 2). 
Pharyngeal swabbing was more sensitive than nasopha-
ryngeal swabbing. Additionally, genotypic methods of 
capsular group characterisation were more sensitive and 
specific than phenotypic methods. However, results from 
direct swab PCR were less conclusive, and due to varying 
methodologies in studies, assessment of its sensitivity and 
specificity cannot be definitively assessed in this review. 
In most cases, it was more sensitive than isolate PCR but 
potentially less specific. However, it should be noted that 
a variety of PCR primers for identifying N. meningitidis 
were used for cultured isolates across studies.
Most included studies received a medium risk-of-bias 
score, mostly because study population characteristics 
were not reported (online supplementary table 4). No 
study was excluded from the review based on the quality 
score, and no study received a high risk-of-bias score to 
necessitate the pre-specified sensitivity analysis. However, 
the results further indicated a need for clear reporting of 
methodology and standardisation.
Carriage by WhO region
In the African region, all studies were from countries 
located in the meningitis belt. Most studies included 
both children and adults (at least to age 29). The overall 
carriage prevalence was, typically, lower than other WHO 
regions and ranged from 1.7% among 1–29-year olds 
in Burkina Faso to 13.2% among 10–18-year olds in the 
Gambia. ‘Other’ serogroups were less frequently iden-
tified compared with other regions. Depending on the 
year, serogroup W, X or Y was the most commonly carried 
disease-causing serogroup in Burkina Faso, and sero-
group W was the most common in countries in the rest of 
the region (online supplementary table 5).
In the region of the Americas, studies were almost 
exclusively conducted among adolescents and university 
students. The overall carriage prevalence ranged from 
4.0% in Chilean university students to 71.1% in Brazilian 
university students. ‘Other’ serogroups were the most 
commonly carried in all studies, except one. Among 
serogroups A, B, C, W, X and Y, B was the most prevalent 
across the region. Serogroups C and Y were identified as 
the most common for select years in Latin America.
Only one study was identified from the Eastern Medi-
terranean region. Iranian students, 7–19 years old, had 
an overall carriage prevalence of 8.9%, with the highest 
carriage among 15–19-year olds. The vast majority of 
carriage was of serogroup C, with lower prevalence of 
serogroup B found.
As in the Americas, most studies from the European 
region focused on adolescents and university students. 
The overall carriage prevalence ranged from 5.3% in 
Italian 14–21-year olds to 61.9% in English university 
students. Serogroups B, Y and ‘other’ were the most 
prominent across the majority of the region. However, 
serogroup W was the most commonly carried in Turkey 
and was a prominent serogroup identified in a 2015–2016 
carriage study in England.
In the South-East Asia region, only one study among 
Indian university students was eligible for inclusion, and 
only low levels of serogroup B carriage were identified.
The vast majority of studies from the Western Pacific 
region were from China, and, typically, included both chil-
dren and adults. The overall carriage prevalence ranged 
from 0% in Guangzhou in 2009 to 33.7% in Laibin in 
2011, cities in neighbouring provinces. Carriage results 
from China were more variable than other regions with 
no apparent pattern by age, year or province. The most 
commonly carried serogroups were A, B and C, but sero-
groups A, B, C, W, X, Y and ‘other’ were each identified as 
the most prominent in at least one study. Elsewhere in the 
region, adolescents and university students were sampled 
and serogroups B and ‘other’ were the most common.
Age group meta-analysis
In total, six studies from the African region, seven from 
the region of the Americas and eight from the Euro-
pean region were included in the meta-analyses. Only 
for the African region were there sufficient data for anal-
ysis for all age groups. For the regions of the Americas 
and Europe, analyses were restricted to the age groups 
for which data from at least three studies were available. 
There were insufficient studies or responses received 
from the Eastern Mediterranean, South-East Asia and 
Western Pacific regions for meta-analysis.
Carriage across the lifespan in the African region
There was a similar pattern of serogroup carriage across 
almost all age groups within Africa, and carriage estimates 
were the highest during childhood and adolescence (5–17-
year olds) (figure 2). Within the majority of age groups, the 
carriage of ‘other’ was higher than the six disease-associated 
serogroups. The second most commonly carried group was 
serogroup W, rates of which were comparable to ‘other’ 
for many age groups. Heterogeneity was high (I2≥75%) for 
serogroups W, X, Y and ‘other’ in many age groups (online 
supplementary table 6).
Carriage in 18–24-Year Olds in the region of the Americas
Carriage estimates were extremely low (<0.1%) for 
serogroups A, W, X and Y, while ‘other’ had the highest 
carriage estimate of 11.5% (95% CI 7.6% to 16.1%) 
(figure 3). B and C represented the most prevalent of 
the disease-associated serogroups, with a prevalence of 
1.6% (95% CI 0.8% to 2.6%) and 2.5% (<0.1%–7.8%), 
respectively. Heterogeneity was high (I2 ≥75%) for sero-
groups B, C and ‘other,’ and low (I2<50%) for sero-
groups A, W, X and Y (online supplementary table 6).
Carriage in 11–17-year olds and 18–24-year Olds in the European 
region
In the 11–17-year olds, serogroups A, C, W, X and Y each 
had <1% prevalence (figure 4). Serogroup B and ‘other’ 
had a prevalence of 1.9% (95% CI 1.3% to 2.7%) and 
3.2% (1.0%–6.6%), respectively. Heterogeneity was 
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moderately high (50% ≤I2<75%) for serogroups C and 
W, and high (I2 ≥75%) for ‘other’. In the 18–24-year olds, 
serogroups B (5.0%, 95% CI 3.0% to 7.5%), Y (3.9%, 
95% CI 1.3% to 7.8%) and ‘other’ (6.4%, 95% CI 3.1% 
to 10.8%) were the most prevalent. As in the 11–17--
year olds, carriage of serogroups A, C, W and X were 
less common. Heterogeneity was moderately high (50% 
≤I2<75%) for serogroup C and high (I2 ≥75%) for sero-
groups B, W, Y and ‘other’.
DIsCussIOn
To our knowledge, this is the first systematic review to 
explore serogroup-specific meningococcal carriage by 
age group globally. Additionally, our study highlights 
the lack of standard methodology for assessing meningo-
coccal carriage. Since, outside of China and Africa, the 
majority of studies were conducted in adolescents and 
young adults, our understanding of serogroup-specific 
carriage and potential transmission in other age groups 
is limited. In Africa, the only region with the requisite 
data to investigate carriage patterns of different sero-
groups across age ranges, the patterns appeared similar 
for all serogroups where a peak was seen from childhood 
to adolescence (5–17-year olds). Additional multi-site 
studies across lifespan would be required to evaluate the 
lifespan dynamics in other regions.
Although the burden of IMD is high in Africa, carriage 
is low, with no serogroup-specific meta-estimate greater 
Figure 2 Meningococcal carriage in the African region across the lifespan (in years) stratified by serogroup. The number of 
data points included for each age meta-estimate are reported after the age group label. ‘Other’ includes both non-encapsulated 
and other capsulated (eg, E, Z).
Figure 3 Meningococcal carriage in the region of the Americas in 18–24-year olds stratified by serogroup. The number of 
data points included for each age meta-estimate are reported after the age group label. ‘Other’ includes both non-encapsulated 
and other capsulated (eg, E, Z).
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than 1.3% and the majority below 0.5%. Along with the 
peak in carriage in 5–17-year olds, estimates for sero-
groups W and ‘other’ increased slightly among adults aged 
30–64 and 30–49, respectively. This is, perhaps, a point 
for future investigation. Although serogroup Y carriage 
was identified, it causes few cases of IMD in the region.12 
It should be noted that carriage distribution within the 
meningitis belt is variable and likely influenced by circu-
lating pathogenic strains, even if the overall carriage 
remains low.13 The MenA campaign has dramatically 
decreased the disease due to serogroup A in the region 
and induced herd immunity by decreasing group A 
carriage, supporting introduction of MenA into national 
childhood immunisation schedules to provide prolonged 
protection against this serogroup.14 15 Consideration 
should also be given to expanding conjugate vaccination 
to other serogroups causing outbreaks in the region, such 
as C and W.16 17
In the Americas, the primary disease-associated sero-
groups carried were B and C, similar to IMD serogroups 
in the region.12 Carriage of ‘other’ groups was highest 
in the Americas where there is a higher non-groupable 
carriage prevalence in North America compared with 
other regions. Group C-containing vaccines have been 
introduced in several countries in the region, which can 
decrease carriage of this group. While group C was preva-
lent in the regional meta-analysis, low levels of C carriage 
were identified in all studies except one, which reports 
a prevalence of 46%. This outlier raises an important 
point about the sensitivity of the methods used to detect 
carriage, which is discussed in more detail below.
Within the European region, a high carriage prevalence 
of serogroups B and Y was found, which in this case is 
similar to the serogroups most responsible for IMD cases 
in the region. ‘Other’ groups, as expected, are propor-
tionally more prevalent among carriers than in IMD 
cases.18 A significant decrease in serogroup C carriage is 
seen after national MenC vaccination, thereby inducing 
herd immunity.8 All studies from the European region 
included in this review except one were conducted after 
national MenC introduction, which likely contributed to 
the low levels of serogroup C carriage identified in this 
review. The carriage of serogroups B, C, Y and ‘other’ 
was substantially higher in the 18–24-year olds compared 
with the 11–17-year olds. Acquisition of these serogroups 
is likely driving the increase in overall carriage, which is 
estimated to peak at age 19 in the region.6
The vast majority of studies among all ages from the 
Western Pacific region were from China, where sero-
groups A, B and C were common. This is in line with 
recent increases in IMD caused by serogroup B and 
the known circulation of serogroups A and C.19 Although 
polysaccharide vaccines against serogroups A and C are 
included in the national immunisation schedule, they 
do not disrupt carriage and induce herd immunity, 
explaining the frequent carriage of these serogroups.19 
Future research is needed to elucidate when the overall 
carriage peaks in the region, because the determination 
of the primary disease transmitters would impact the 
targeted age group for national vaccination policies.
Because only a few studies were conducted in the Eastern 
Mediterranean and South-East Asia regions, or in much 
of the Western Pacific region, uncertainty about the prev-
alent serogroups being carried and how they compare to 
disease in these regions remains. Although current IMD 
serogroup data from Iran are few, serogroups B and C 
were identified as leading causes of meningitis cases in 
Tehran.20 Conversely, the one study from South-East Asia 
Figure 4 Meningococcal carriage in the European region in 11–17-year olds and 18–24-year olds stratified by serogroup. The 
number of data points included for each age meta-estimate are reported after the age group label. ‘Other’ includes both non-
encapsulated and capsulated (eg, E, Z).
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found university students in India to only carry serogroup 
B, which rarely causes disease within the country.21 Addi-
tional studies are needed to confirm if these results are 
more widely generalisable to other countries within the 
regions.
There are several carriage studies that are either being 
conducted or were recently completed. These include the 
‘B Part of It’ study among Australian adolescents and young 
adults (trial registries: NCT03089086, NCT03419533 
and ACTRN12617000233325), the ‘UKMenCar4’ study 
among adolescents in the UK (ISRCTN72009783 and 
ISRCTN98439755) and a study among young adults in 
Japan (trial registry: JPRN-UMIN000026546). While 
these studies will provide valuable information, especially 
concerning herd immunity and invasiveness, additional 
studies should be considered as data gaps remain in many 
countries and regions.
laboratory methods and their effect on carriage detection
How samples of N. meningitidis are handled and the labo-
ratory methods used can impact carriage detection. Two 
literature reviews of methodology suggest that swabs 
taken from the posterior pharyngeal wall, and maybe 
the tonsils, are more sensitive than nasopharyngeal 
swabs or oral washes.22 23 This is in agreement with the 
results from Esposito et al’s study included in this review 
that compared these techniques.24 Other factors in study 
design and implementation that can affect detection 
include the type of swab used, immediate plating versus 
using a transport medium and time to arrival at the labo-
ratory for processing.22 23
Results from studies included in this review suggest that 
conventional microbiological methods, such as imme-
diate plating for culture, might be less sensitive than PCR 
analysis of DNA taken directly from the swab or growth 
in Todd-Hewitt broth in some, but not all, cases.25–29 
The difference in sensitivity was most noticeable for age 
groups with the highest carriage and ‘other’ groups but 
was sometimes important for disease-associated groups 
as well. This is an important consideration since carriage 
density is variable, the importance of which and impli-
cations for disease transmission are still being studied.30 
The matter is further complicated if carriage density 
varies across lifespan.
How the pathogen and serogroups are determined is 
also important for sensitivity. Several studies from this 
review evaluated the use of agglutination and PCR tests 
to determine the serogroup or genogroup, respectively. 
PCR was universally more specific compared with agglu-
tination, and sensitivity varied for isolate PCR culture 
versus direct swab PCR.27–29 31–37 When using PCR for 
detection and genogrouping, it is important to carefully 
select the primers to avoid inadvertently underestimating 
carriage. This is especially true for non-groupable speci-
mens as they may lack the ctrA capsular transport gene, 
which is often used for N. meningitidis detection. As such, 
the addition of primers for another target, such as sodC 
and/or porA, might be appropriate.38 39
These concerns will continue to abound and make 
future analyses difficult. This is especially true as new 
techniques, such as direct PCR analysis of pharyngeal 
swabs as employed in studies by Gilca et al, Rizek et al, 
Jeppessen et al, and van Ravenhorst et al, increase in popu-
larity.25 27–29 Additional research is needed to determine 
the most sensitive and effective methods for carriage 
detection and characterisation. Standardised methodolo-
gies for carriage studies would be welcomed.
However, even if a ‘gold standard’ methodology is 
agreed on, trends by capsular group and age group might 
not be found due to myriad other influencing factors, 
such as strain variability, unpredictable outbreaks, and 
variable risk factors for carriage. This is highlighted in the 
MenAfriCar study included in this review, which utilised 
standardised methodology in seven countries within the 
African Meningitis Belt.40 Even still, considerable differ-
ences are noted in carriage prevalences, at times within 
the same country as seen in Senegal. Reasons for this are 
complex and, as such, elucidation of trends by age and 
capsular group, if they exist, could continue to be difficult.
strengths and limitations
Strengths of this study include the comprehensive liter-
ature review, including two Chinese databases. To our 
knowledge, this is the first systematic review and meta-anal-
ysis of meningococcal carriage by both serogroup and age 
group. An additional strength includes seeking data from 
authors for meta-analyses. Although not all regions or 
age groups were able to be analysed, those that were anal-
ysed provided initial estimates of the interplay between 
age and serogroup carriage.
Limitations of this review include the inability to 
conduct meta-analyses in all regions where data were 
available, such as in China, and variability in the meth-
odology of the studies included. As discussed above, 
the study methodology can affect the sensitivity to detect 
carriage, which, in turn, can affect the results of this review 
by decreasing the estimated prevalence. Important chal-
lenges to this review include the variability of meningo-
coccal epidemiology temporally and geographically. In 
order to mitigate this limitation, we included studies 
only from 2007 to 2016 and examined by WHO region. 
However, we recognise that the epidemiological situa-
tion is still variable in this time frame, even year-to-year 
within the same country. Additionally, neither direct nor 
indirect vaccine effects were accounted for in the anal-
ysis, both of which can have substantial impact on the 
carriage of the targeted capsular groups.7 Limitations 
notwithstanding, we believe this review will be beneficial 
to infectious disease specialists, researchers and policy 
makers who wish to gain a better understanding of the 
serogroup-specific studies recently conducted and the 
prominent serogroups carried.
COnClusIOns
Our review provides a thorough evaluation of meningo-
coccal carriage studies from 2007 to 2016 reporting age 
8 Peterson ME, et al. BMJ Open 2019;9:e024343. doi:10.1136/bmjopen-2018-024343
Open access 
and serogroup data. Due to paucity of data eligible for 
inclusion in meta-analyses, clear and robust conclusions 
about the variation of capsular group-specific carriage 
across all age groups and WHO regions were unable to 
be determined. The data reported in this review should 
be used in conjunction with local disease epidemiology 
when evaluating the ages most responsible for transmis-
sion and establishing targeted vaccination policies, as 
high carriage prevalence does not necessarily correlate 
with high disease risk. Carriage studies will continue to 
be important as MenACWY and MenB vaccines are more 
widely introduced, since their impact on carriage, and the 
subsequent development of herd immunity, is not yet fully 
understood. However, this cannot be done effectively if 
carriage methodology and sensitivity differ substantially 
between studies. It is, therefore, of great importance that 
research studies continue to elucidate a standard meth-
odology for carriage detection.
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